Logo Image

Barbara Pistilli

Articles by Barbara Pistilli

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

ByBarbara Pistilli,Rachel M. Layman,Giuseppe Curigliano,Massimo Cristofanilli, MD,Robert Wesolowski,Hyo S Han,Antonio Giordano,Igor Gorbatchevsky,Sara A. Hurvitz, MD

Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study

BySara M. Tolaney, MD, MPH,Evandro de Azambuja,Kevin Kalinsky, MD, MS,Sherene Loi, MD, PhD,Sung-Bae Kim,Clinton Yam,Bernardo Rapoport, MD,Seock-Ah Im,Barbara Pistilli,Wassim McHayleh,David W. Cescon,Junichiro Watanabe,Manuel Alejandro Lara Banuelas,Ruffo Freitas-Junior,Javier Salvador Bofill,Maryam Afshari,Dianna Gary,Lu Wang,Catherine Lai, MD, MPH,Peter Schmid, MD

82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer

ByBarbara Pistilli,Livia Pierotti,Magali Lacroix-Triki,Cecile Vicier,Jean-Sebastien Frenel,Véronique D’Hondt,Florence Dalenc,Thomas Bachelot,Agnes Ducoulombier,Marc-Antoine Benderra,Delphine Loirat,Didier Mayeur,Ghada B. Nachabeh,Andrea Sporchia,Fumitaka Suto,Stefan Michiels,Noemie Corcos,Fernanda Mosele,Fabrice André, Guillaime Montagnac
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri,Seock-Ah Im,Senia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez Jañez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen-Shen Lu,Erika P. Hamilton, MD,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky, MD, MS,Lu Xu,Neelima Denduluri,Binghe Xu,Barbara Pistilli

Latest Updated Articles